Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $31
Benzinga Newsdesk 12 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $33 to $31.
Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $33 to $31.